Opportunities and challenges in the development of kinase inhibitor therapy for cancer

Genes and Development

Volumn 17, Issue 24, 2003, Pages 2998-3010

  Sawyers, Charles L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; AMINO ACID; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FLT3 LIGAND; GEFITINIB; IMATINIB; PHOSPHOTRANSFERASE INHIBITOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; RAF PROTEIN; RAPAMYCIN; STEM CELL FACTOR; TEMSIROLIMUS; TRASTUZUMAB;

ALLELE; AMINO ACID ANALYSIS; CANCER CELL; CANCER CHEMOTHERAPY; CANCER GENETICS; CANCER PATIENT; CANCER SURVIVAL; CHROMOSOME DELETION; CHROMOSOME TRANSLOCATION; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DISEASE COURSE; DRUG ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; DRUG SCREENING; DRUG SENSITIVITY; DRUG TARGETING; ENZYME ACTIVATION; ENZYME INHIBITION; GENE EXPRESSION; GENE MUTATION; GENETIC ANALYSIS; HEMATOPOIETIC CELL; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; INHIBITION KINETICS; LUNG CANCER; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; METHODOLOGY; MOLECULAR MECHANICS; MUTATION; NONHUMAN; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROTEIN TARGETING; REVIEW; TREATMENT FAILURE;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; DRUG DESIGN; ENZYME INHIBITORS; HUMANS; NEOPLASMS; PROTEIN-TYROSINE KINASES;

EID: 0345184913     PISSN: 08909369     EISSN: None     Source Type: Journal    
DOI: 10.1101/gad.1152403     Document Type: Review

References (101)

1. Abraham, R.T. 2002. Identification of TOR signaling complexes: More TORC for the cell growth engine. Cell 111: 9-12.
2. Ahuja, H., Bar-Eli, M., Advani, S.H., Benchimol, S., and Cline, M.J. 1989. Alterations in the p53 gene and the clonal evolution of the blast crisis of chronic myelocytic leukemia. Proc. Natl. Acad. Sci. 86: 6783-6787.
3. Allander, S.V., Nupponen, N.N., Ringner, M., Hostetter, G., Maher, G.W., Goldberger, N., Chen, Y., Carpten, J., Elkahloun, A.G., and Meltzer, P.S. 2001. Gastrointestinal stromal tumors with KIT mutations exhibit a remarkably homogeneous gene expression profile. Cancer Res. 61: 8624-8628.
4. Antonyak, M.A., Moscatello, D.K., and Wong, A.J. 1998. Constitutive activation of c-Jun N-terminal kinase by a mutant epidermal growth factor receptor. J. Biol. Chem. 273: 2817-2822.
5. Apperley, J.F., Gardembas, M., Melo, J.V., Russell-Jones, R., Bain, B.J., Baxter, E.J., Chase, A., Chessells, J.M., Colombat, M., Dearden, C.E., et al. 2002. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor β. N. Engl. J. Med. 347: 481-487.
6. Armstrong, S.A., Kung, A.L., Mabon, M.E., Silverman, L.B., Stam, R.W., Den Boer, M.L., Pieters, R., Kersey, J.H., Sallan, S.E., Fletcher, J.A., et al. 2003. Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification. Cancer Cell 3: 173-183.
7. Azam, M., Latek, R.R., and Daley, G.Q. 2003. Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell 112: 831-843.
8. Bardelli, A., Parsons, D.W., Silliman, N., Ptak, J., Szabo, S., Saha, S., Markowitz, S., Willson, J.K., Parmigiani, G., Kinzler, K.W., et al. 2003. Mutational analysis of the tyrosine kinome in colorectal cancers. Science 300: 949.
9. Baselga, J., Rischin, D., Ranson, M., Calvert, H., Raymond, E., Kieback, D.G., Kaye, S.B., Gianni, L., Harris, A., Bjork, T., et al. 2002. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J. Clin. Oncol. 20: 4292-4302.
10. Bianco, R., Shin, I., Ritter, C.A., Yakes, F.M., Basso, A., Rosen, N., Tsurutani, J., Dennis, P.A., Mills, G.B., and Arteaga, C.L. 2003. Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene 22: 2812-2822.
11. Branford, S., Walsh, S., Rudzki, Z., Grigg, A., Taylor, K., Durrant, S., Arthur, C., Browett, P., Schwarer, A., Ma, D., et al. 2002. Imatinib produces significantly superior molecular responses compared to interferon plus low dose Ara-C in patient with newly diagnosed chronic myeloid leukaemia in chronic phase. Proc. Am. Soc. Hematology Abstr.: 352.
12. Branford, S., Rudzki, Z., Walsh, S., Parkinson, I., Grigg, A., Szer, J., Taylor, K., Herrmann, R., Seymour, J.F., Arthur, C., et al. 2003. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 102: 276-283.
13. Brazil, D.P., Park, J., and Hemmings, B.A. 2002. PKB binding proteins. Getting in on the Akt. Cell 111: 293-303.
14. Buchdunger, E., Zimmermann, J., Mett, H., Meyer, T., Muller, M., Regenass, U., and Lydon, N.B. 1995. Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class. Proc. Natl. Acad. Sci. 92: 2558-2562.
15. Burton, A. 2002. What went wrong with Iressa? Lancet Oncol. 3: 708.
16. Cantley, L.C. 2002. The phosphoinositide 3-kinase pathway. Science 296: 1655-1657.
17. Cantley, L.C. and Neel, B.G. 1999. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/ AKT pathway. Proc. Natl. Acad. Sci. 96: 4240-4245.
18. Cappuzzo, F., Gregorc, V., Rossi, E., Cancellieri, A., Magrini, E., Paties, C.T., Ceresoli, G., Lombardo, L., Bartolini, S., Calandri, C., et al. 2003. Gefitinib in pretreated non-small-cell lung cancer (NSCLC): Analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC. J. Clin. Oncol. 21: 2658-2663.
19. Chen, W.S., Xu, P.Z., Gottlob, K., Chen, M.L., Sokol, K., Shiyanova, T., Roninson, I., Weng, W., Suzuki, R., Tobe, K., et al. 2001. Growth retardation and increased apoptosis in mice with homozygous disruption of the Aktl gene. Genes & Dev. 15: 2203-2208.
20. Chin, L., Tam, A., Pomerantz, J., Wong, M., Holash, J., Bardeesy, N., Shen, Q., O'Hagan, R., Pantginis, J., Zhou, H., et al. 1999. Essential role for oncogenic Ras in tumour maintenance. Nature 400: 468-472.
21. Cho, H., Mu, J., Kim, J.K., Thorvaldsen, J.L., Chu, Q., Crenshaw III, E.B., Kaestner, K.H., Bartolomei, M.S., Shulman, G.I., and Birnbaum, M.J. 2001. Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB beta). Science 292: 1728-1731.
22. Choe, G., Horvath, S., Cloughesy, T.F., Crosby, K., Seligson, D., Palotie, A., Inge, L., Smith, B.L., Sawyers, C.L., and Mischel, P.S. 2003. Analysis of the phosphatidylinositol 3′-kinase signaling pathway in glioblastoma patients in vivo. Cancer Res. 63: 2742-2746.
23. Choi, Y.-J., Fanidi, A., White, S., Lyons, J., Wilhelm, S., Wang, Q., and Bollag, G. 2003. The novel Raf inhibitor BAY 43-9006 blocks signaling and proliferation in BRAF mutant and wildtype melanoma and coloretal tumor cell lines. Proc. Am. Assoc. Cancer Res. Abstr.: 270.
24. Cohen, M.H., Williams, G.A., Sridhara, R., Chen, G., and Pazdur, R. 2003. FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets. Oncologist 8: 303-306.
25. Cools, J., DeAngelo, D.J., Gotlib, J., Stover, E.H., Legare, R.D., Cortes, J., Kutok, J., Clark, J., Galinsky, I., Griffin, J.D., et al. 2003. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N. Engl. J. Med. 348: 1201-1214.
26. Dancey, J.E. 2002. Clinical development of mammalian target of rapamycin inhibitors. Hematol. Oncol. Clin. North Am. 16: 1101-1114.
27. Dancey, J.E. and Freidlin, B. 2003. Targeting epidermal growth factor receptor - Are we missing the mark? Lancet 362: 62-64.
28. Dancey, J. and Sausville, E.A. 2003. Issues and progress with protein kinase inhibitors for cancer treatment. Nat. Rev. Drug Discov. 2: 296-313.
29. Davies, H., Bignell, G.R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M.J., Bottomley, W., et al. 2002. Mutations of the BRAF gene in human cancer. Nature 417: 949-954.
30. Demetri, G.D., von Mehren, M., Blanke, C.D., Van den Abbeele, A.D., Eisenberg, B., Roberts, P.J., Heinrich, M.C., Tuveson, D.A., Singer, S., Janicek, M., et al. 2002. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N. Engl. J. Med. 347: 472-480.
31. Druker, B.J. 2002. Perspectives on the development of a molecularly targeted agent. Cancer Cell 1: 31-36.
32. Druker, B.J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G.M., Fanning, S., Zimmermann, J., and Lydon, N.B. 1996. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med. 2: 561-566.
33. Druker, B.J., Sawyers, C.L., Kantarjian, H., Resta, D.J., Reese, S.F., Ford, J.M., Capdeville, R., and Talpaz, M. 2001a. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N. Engl. J. Med. 344: 1038-1042.
34. Druker, B.J., Talpaz, M., Resta, D.J., Peng, B., Buchdunger, E., Ford, J.M., Lydon, N.B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., et al. 2001b. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344: 1031-1037.
35. Felsher, D.W. and Bishop, J.M. 1999. Reversible tumorigenesis by MYC in hematopoietic lineages. Mol. Cell 4: 199-207.
36. Foran, J., O'Farrell, A.-M., Fiedler, W., Serve, H., Paquette, R., Cooper, M., Heinrich, M.C., Kim, H., Yuen, H.A., Louie, S.G., et al. 2002. An innovative single dose clinical study shows potent inhibition of FLT3 phosphorylation by SU11248 in vivo; A clinical and pharmocodynamic study in AML patients. Proc. Am. Soc. Hematology Abstr.: 2196.
37. Foti, A., Ahuja, H.G., Allen, S.L., Koduru, P., Schuster, M.W., Schulman, P., Bar-Eli, M., and Cline, M.J. 1991. Correlation between molecular and clinical events in the evolution of chronic myelocytic leukemia to blast crisis. Blood 77: 2441-2444.
38. Foukas, L.C. and Okkenhaug, K. 2003. Gene-targeting reveals physiological roles and complex regulation of the phosphoinositide 3-kinases. Arch. Biochem. Biophys. 414: 13-18.
39. Frederick, L., Wang, X.Y., Eley, G., and James, C.D. 2000. Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res. 60: 1383-1387.
40. Fruman, D.A., Snapper, S.B., Yballe, C.M., Alt, F.W., and Cantley, L.C. 1999. Phosphoinositide 3-kinase knockout mice: Role of p85alpha; in B cell development and proliferation. Biochem. Soc. Trans. 27: 624-629.
41. Fukuoka, M., Yano, S., Giaccone, G., Tamura, T., Nakagawa, K., Douillard, J.Y., Nishiwaki, Y., Vansteenkiste, J., Kudoh, S., Rischin, D., et al. 2003. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J. Clin. Oncol. 21: 2237-2246.
42. Golub, T.R., Barker, G.F., Lovett, M., and Gilliland, D.G. 1994. Fusion of PDGF receptor β to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell 77: 307-316.
43. Gorre, M.E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P.N., and Sawyers, C.L. 2001. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293: 876-880.
44. Grunwald, V., DeGraffenried, L., Russel, D., Friedrichs, W.E., Ray, R.B., and Hidalgo, M. 2002. Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells. Cancer Res. 62: 6141-6145.
45. Heinrich, M.C., Druker, B.J., Curtin, P.T., Paquette, R., Sawyers, C.L., DeAngelo, D.J., Gilliland, G.D., Stone, R., Caliguiri, M., Byrd, M.A., et al. 2002. A "first in man" study of the safety and PK/PD of an oral FLT inhibitor (MLN518) in patients with AML or high risk myelodysplasia. Proc. Am. Soc. Hematology Abstr.: 1305.
46. Heinrich, M.C., Corless, C.L., Demetri, G.D., Blanke, C.D., von Mehren, M., Joensuu, H., McGreevey, L.S., Chen, C.J., Van den Abbeele, A.D., Druker, B.J., et al. 2003a. Kinase mutations and imatinib mesylate response in patients with metastatic gastrointestinal stromal tumor. J. Clin. Oncol. (in press).
47. Heinrich, M.C., Corless, C.L., Duensing, A., McGreevey, L., Chen, C.J., Joseph, N., Singer, S., Griffith, D.J., Haley, A., Town, A., et al. 2003b. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 299: 708-710.
48. Heitman, J., Movva, N.R., and Hall, M.N. 1991. Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science 253: 905-909.
49. Herbst, R.S., Maddox, A.M., Rothenberg, M.L., Small, E.J., Rubin, E.H., Baselga, J., Rojo, F., Hong, W.K., Swaisland, H., Averbuch, S.D., et al. 2002. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: Results of a phase I trial. J. Clin. Oncol. 20: 3815-3825.
50. Hirota, S., Isozaki, K., Moriyama, Y., Hashimoto, K., Nishida, T., Ishiguro, S., Kawano, K., Hanada, M., Kurata, A., Takeda, M., et al. 1998. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279: 577-580.
51. Huang, H.S., Nagane, M., Klingbeil, C.K., Lin, H., Nishikawa, R., Ji, X.D., Huang, C.M., Gill, G.N., Wiley, H.S., and Cavenee, W.K. 1997. The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling. J. Biol. Chem. 272: 2927-2935.
52. Inoki, K., Li, Y., Zhu, T., Wu, J., and Guan, K.L. 2002. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat. Cell Biol. 4: 648-657.
53. Joensuu, H., Roberts, P.J., Sarlomo-Rikala, M., Andersson, L.C., Tervahartiala, P., Tuveson, D., Silberman, S., Capdeville, R., Dimitrijevic, S., Druker, B., et al. 2001. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N. Engl. J. Med. 344: 1052-1056.
54. Kiyoi, H., Naoe, T., Yokota, S., Nakao, M., Minami, S., Kuriyama, K., Takeshita, A., Saito, K., Hasegawa, S., Shimodaira, S., et al. 1997. Internal tandem duplication of FLT3 associated with leukocytosis in acute promyelocytic leukemia. Leukemia Study Group of the Ministry of Health and Welfare (Kohseisho). Leukemia 11: 1447-1452.
55. Levis, M., Allebach, J., Tse, K.F., Zheng, R., Baldwin, B.R., Smith, B.D., Jones-Bolin, S., Ruggeri, B., Dionne, C., and Small, D. 2002. A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo. Blood 99: 3885-3891.
56. Libermann, T.A., Nusbaum, H.R., Razon, N., Kris, R., Lax, I., Soreq, H., Whittle, N., Waterfield, M.D., Ullrich, A., and Schlessinger, J. 1985. Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin. Nature 313: 144-147.
57. Liotta, L.A., Espina, V., Mehta, A.I., Calvert, V., Rosenblatt, K., Geho, D., Munson, P.J., Young, L., Wulfkuhle, J., and Petricoin, E.F. 2003. Protein microarrays: Meeting analytical challenges for clinical applications. Cancer Cell 3: 317-325.
58. Lorusso, P.M. 2003. Phase I studies of ZD1839 in patients with common solid tumors. Semin. Oncol. 30: 21-29.
59. Ma, Y., Zeng, S., Metcalfe, D.D., Akin, C., Dimitrijevic, S., Butterfield, J.H., McMahon, G., and Longley, B.J. 2002. The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. Blood 99: 1741-1744.
60. Manning, B.D., Tee, A.R., Logsdon, M.N., Blenis, J., and Cantley, L.C. 2002. Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. Mol. Cell 10: 151-162.
61. Moss, K.G., Toner, G.C., Cherrington, J.M., Mendel, D.B., and Laird, A.D. 2003. Hair depigmentation is a biological readout for pharmacological inhibition of KIT in mice and humans. J. Pharmacol. Exp. Ther. 307: 476-480.
62. Nagar, B., Bornmann, W.G., Pellicena, P., Schindler, T., Veach, D.R., Miller, W.T., Clarkson, B., and Kuriyan, J. 2002. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI571). Cancer Res. 62: 4236-4243.
63. Nakao, M., Yokota, S., Iwai, T., Kaneko, H., Horiike, S., Kashima, K., Sonoda, Y., Fujimoto, T., and Misawa, S. 1996. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia 10: 1911-1918.
64. Neshat, M.S., Mellinghoff, I.K., Tran, C., Stiles, B., Thomas, G., Petersen, R., Frost, P., Gibbons, J.J., Wu, H., and Sawyers, C.L. 2001. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc. Natl. Acad. Sci. 98: 10314-10319.
65. Neubauer, A., Brendel, C., Vogel, D., Schmidt, C.A., Heide, I., and Huhn, D. 1993. Detection of p53 mutations using non-radioactive SSCP analysis: p53 is not frequently mutated in myelodysplastic syndromes (MDS). Ann. Hematol. 67: 223-226.
66. Okkenhaug, K., Bilancio, A., Farjot, G., Priddle, H., Sancho, S., Peskett, E., Pearce, W., Meek, S.E., Salpekar, A., Waterfield, M.D., et al. 2002. Impaired B and T cell antigen receptor signaling in p110δ PI 3-kinase mutant mice. Science 297: 1031-1034.
67. Pegram, M., Hsu, S., Lewis, G., Pietras, R., Beryt, M., Sliwkowski, M., Coombs, D., Baly, D., Kabbinavar, F., and Slamon, D. 1999. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 18: 2241-2251.
68. Pietras, R.J., Fendly, B.M., Chazin, V.R., Pegram, M.D., Howell, S.B., and Slamon, D.J. 1994. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene 9: 1829-1838.
69. +/- mice. Proc. Natl. Acad. Sci. 98: 10320-10325.
70. Potter, C.J., Pedraza, L.G., and Xu, T. 2002. Akt regulates growth by directly phosphorylating Tsc2. Nat. Cell Biol. 4: 658-665.
71. Prados, M., Chang, S., Burton, E., Kapadia, A., Rabbitt, J., Page, M., Federhoff, A., Kelley, S., Fyfe, G., University of California San Francisco, and Genentech, Inc. 2003. Phase I study of OSI-774 alone or with temozolomide in patients with malignant glioma. Proc. Am. Soc. Clin. Oncology Abstr.: 394.
72. Rubin, B.P., Schuetze, S.M., Eary, J.F., Norwood, T.H., Mirza, S., Conrad, E.U., and Bruckner, J.D. 2002. Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans. J. Clin. Oncol. 20: 3586-3591.
73. Salomon, A.R., Ficarro, S.B., Brill, L.M., Brinker, A., Phung, Q.T., Ericson, C., Sauer, K., Brock, A., Horn, D.M., Schultz, P.G., et al. 2003. Profiling of tyrosine phosphorylation pathways in human cells using mass spectrometry. Proc. Natl. Acad. Sci. 100: 443-448.
74. Sawyers, C.L. 1999. Chronic myeloid leukemia. N. Engl. J. Med. 340: 1330-1340.
75. -. 2002a. Finding the next Gleevec: FLT3 targeted kinase inhibitor therapy for acute myeloid leukemia. Cancer Cell 1: 413-415.
76. -. 2002b. Imatinib GIST keeps finding new indications: Successful treatment of dermatofibrosarcoma protuberans by targeted inhibition of the platelet-derived growth factor receptor. J. Clin. Oncol. 20: 3568-3569.
77. Sawyers, C.L. and Denny, C.T. 1994. Chronic myelomonocytic leukemia: Tel-a-kinase what Ets all about. Cell 77: 171-173.
78. Sawyers, C.L., Hochhaus, A., Feldman, E., Goldman, J.M., Miller, C.B., Ottmann, O.G., Schiffer, C.A., Talpaz, M., Guilhot, F., Deininger, M.W., et al. 2002. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: Results of a phase II study. Blood 99: 3530-3539.
79. Schindler, T., Bornmann, W., Pellicena, P., Miller, W.T., Clarkson, B., and Kuriyan, J. 2000. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 289: 1938-1942.
80. Schmelzle, T. and Hall, M.N. 2000. TOR, a central controller of cell growth. Cell 103: 253-262.
81. Shah, N.P. and Sawyers, C.L. 2003. Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias. Oncogene 22: 7389-7395.
82. Shah, N.P., Nicoll, J.M., Nagar, B., Gorre, M.E., Paquette, R.L., Kuriyan, J., and Sawyers, C.L. 2002. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2: 117-125.
83. Shai, R., Shi, T., Kremen, T.J., Horvath, S., Liau, L.M., Cloughesy, T.F., Mischel, P.S., and Nelson, S.F. 2003. Gene expression profiling identifies molecular subtypes of gliomas. Oncogene 22: 4918-4923.
84. Shamji, A.F., Nghiem, P., and Schreiber, S.L. 2003. Integration of growth factor and nutrient signaling: Implications for cancer biology. Mol. Cell 12: 271-280.
85. Shi, Y., Gera, J., Hu, L., Hsu, J.H., Bookstein, R., Li, W., and Lichtenstein, A. 2002. Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779. Cancer Res. 62: 5027-5034.
86. Shimizu, A., O'Brien, K.P., Sjoblom, T., Pietras, K., Buchdunger, E., Collins, V.P., Heldin, C.H., Dumanski, J.P., and Ostman, A. 1999. The dermatofibrosarcoma protuberans-associated collagen type Iα 1/platelet-derived growth factor (PDGF) B-chain fusion gene generates a transforming protein that is processed to functional PDGF-BB. Cancer Res. 59: 3719-3723.
87. Sill, H., Goldman, J.M., and Cross, N.C. 1995. Homozygous deletions of the p16 tumor-suppressor gene are associated with lymphoid transformation of chronic myeloid leukemia. Blood 85: 2013-2016.
88. Simon, M.P., Pedeutour, F., Sirvent, N., Grosgeorge, J., Minoletti, F., Coindre, J.M., Terrier-Lacombe, M.J., Mandahl, N., Craver, R.D., Blin, N., et al. 1997. Deregulation of the platelet-derived growth factor B-chain gene via fusion with collagen gene COL1A1 in dermatofibrosarcoma protuberans and giant-cell fibroblastoma. Nat. Genet. 15: 95-98.
89. Singer, S., Rubin, B.P., Lux, M.L., Chen, C.J., Demetri, G.D., Fletcher, C.D., and Fletcher, J.A. 2002. Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors. J. Clin. Oncol. 20: 3898-3905.
90. Sircar, K., Hewlett, B.R., Huizinga, J.D., Chorneyko, K., Berezin, I., and Riddell, R.H. 1999. Interstitial cells of Cajal as precursors of gastrointestinal stromal tumors. Am. J. Surg. Pathol. 23: 377-389.
91. Sommer, G., Agosti, V., Ehlers, I., Rossi, F., Corbacioglu, S., Farkas, J., Moore, M., Manova, K., Antonescu, C.R., and Besmer, P. 2003. Gastrointestinal stromal tumors in a mouse model by targeted mutation of the Kit receptor tyrosine kinase. Proc. Natl. Acad. Sci. 100: 6706-6711.
92. Stone, R.M., Klimek, V., DeAngelo, D.J., Nimer, S., Estey, E., Galinsky, I., Neuberg, D., Yap, A., Fox, E.A., Gilliland, D.G., et al. 2002. PKC412, an oral FLT2 inhibitor, has activity in mutant FLT3 acute myeloid leukema (AML): A phase II clinical trial. Proc. Am. Soc. Hematology Abstr.: 316.
93. Suzuki, H., Terauchi, Y., Fujiwara, M., Aizawa, S., Yazaki, Y., Kadowaki, T., and Koyasu, S. 1999. Xid-like immunodeficiency in mice with disruption of the p85α subunit of phosphoinositide 3-kinase. Science 283: 390-392.
94. Tomasson, M.H., Williams, I.R., Hasserjian, R., Udomsakdi, C., McGrath, S.M., Schwaller, J., Druker, B., and Gilliland, D.G. 1999. TEL/PDGFβR induces hematologic malignancies in mice that respond to a specific tyrosine kinase inhibitor. Blood 93: 1707-1714.
95. van Oosterom, A.T., Judson, I., Verweij, J., Stroobants, S., Donato di Paola, E., Dimitrijevic, S., Martens, M., Webb, A., Sciot, R., Van Glabbeke, M., et al. 2001. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: A phase I study. Lancet 358: 1421-1423.
96. Vivanco, I. and Sawyers, C.L. 2002. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat. Rev. Cancer 2: 489-501.
97. Weisberg, E., Boulton, C., Kelly, L.M., Manley, P., Fabbro, D., Meyer, T., Gilliland, D.G., and Griffin, J.D. 2002. Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. Cancer Cell 1: 433-443.
98. Wellbrock, C., Garnett, M., and Marais, R. 2003. IL-16 B-Raf in melanoma. Pigment Cell Res. 16: 579.
99. Wong, A.J., Bigner, S.H., Bigner, D.D., Kinzler, K.W., Hamilton, S.R., and Vogelstein, B. 1987. Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification. Proc. Natl. Acad. Sci. 84: 6899-6903.
100. Wong, A.J., Ruppert, J.M., Bigner, S.H., Grzeschik, C.H., Humphrey, P.A., Bigner, D.S., and Vogelstein, B. 1992. Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc. Natl. Acad. Sci. 89: 2965-2969.
101. Yang, J.C., Haworth, L., Sherry, R.M., Hwu, P., Schwartzentruber, D.J., Topalian, S.L., Steinberg, S.M., Chen, H.X., and Rosenberg, S.A. 2003. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med. 349: 427-434.